BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250727T031317EDT-0460dncMUB@132.216.98.100
DTSTAMP:20250727T071317Z
DESCRIPTION:Research and Innovation invites you to an exclusive opportunity
  to watch a Nobel Prize Laureate speak from an otherwise private summit.\n
 \nDr. Michael Houghton\, Li Ka Shing Professor of Virology at the Universi
 ty of Alberta\, Canada Excellence Research Chair (CERC) Laureate in Virolo
 gy (2010-2017)\, and 2020 Nobel Prize Laureate\, will deliver a lecture at
  the CERC/C150 Research Chairs 2021 Virtual Symposium.\n\nOne of the world
 's top scientists\, Dr. Houghton was awarded the 2020 Nobel Prize in Physi
 ology or Medicine in recognition of his discovery of the hepatitis C (HCV)
  virus. The discovery he made along with two of his colleagues in 1989 ope
 ned a new field of viral hepatitis research that led to improved blood saf
 ety and groundbreaking HCV treatment. HCV is now the first chronic viral i
 llness that can be cured in virtually all patients.\n\nDr. Houghton's lect
 ure\, 'Getting close to curbing the HCV pandemic\,' will be publicly strea
 med on YouTube on June 8\, 2021 at 12:00 p.m. EDT. \n\n*No registration re
 quired. The link to the YouTube stream will be posted to this page on June
  9.* \n\nAbout Dr. Houghton\n\nDr. Houghton is an international leader in 
 viral hepatitis. In 1989\, his USA laboratory and collaborators identified
  the hepatitis C virus (HCV). He then developed blood tests that have sinc
 e prevented millions of infections from tainted blood donations around the
  world. He also has over 40 years of experience in major pharmaceutical co
 mpanies (Searle\, Chiron\, Novartis). His work at Chiron Corporation was l
 argely responsible for its growth into the third largest USA biotech firm 
 in the 1990s\, ultimately being acquired by Novartis in 2005.\n\nAlong wit
 h Dr. Lorne Tyrrell and a team of experts\, Dr. Houghton is developing a v
 accine against hepatitis C (HCV) through the optimization of both the prod
 uction of cross-neutralizing antibodies and cross-reactive immune response
 s to the different HCV genotypes found among the human population worldwid
 e. \n\nDr. Houghton has authored more than 300 research publications and o
 ver 70 patents. He has received numerous international prizes for his scie
 ntific contributions\, including the Robert Koch Medal (1993)\, the Clinic
 al Lasker Award (2000)\, and the Canadian CLF-CASL gold medal (2012). His 
 passion is the application of biomedical research to prevent disease.\n
DTSTART:20210608T160000Z
DTEND:20210608T173000Z
SUMMARY:'Getting close to curbing the HCV pandemic': A Lecture by Nobel Pri
 ze Laureate Michael Houghton
URL:/research/channels/event/getting-close-curbing-hcv
 -pandemic-lecture-nobel-prize-laureate-michael-houghton-330964
END:VEVENT
END:VCALENDAR